CHMP konkluderede derfor den 24. juli 2008, at fordelene ved perorale lægemidler, der indeholder norfloxacin, ikke opvejer risikoen i forbindelse med kompliceret pyelonefritis.
The CHMP therefore concluded on 24 July 2008 that for oral norfloxacin containing medicinal products the benefit does not outweigh the risk in complicated pyelonephritis.